Amyloidosis News - 2022

A guide to understanding the characteristics, diagnosis, and management of transthyretin amyloidosis is now available for multidisciplinary team members. Read More ›

A new review outlines the applications and limitations of different options for the diagnosis of cardiac amyloidosis. Read More ›

Remission for cardiac light chain amyloidosis for >1 year may be associated with changes in myocardial composition without a reduction in extracellular volume. Read More ›

Cardiologists outline how to spot indicators of amyloidosis, what criteria to use to diagnose the disease, and how to distinguish between types of amyloidosis. Read More ›

Signs of cardiac amyloidosis are present earlier than many clinicians realize, and early diagnosis and treatment should save lives. Read More ›

Recognizing critical differences in genotype and phenotype among patients with transthyretin amyloidosis or other inherited cardiovascular diseases is imperative for optimal outcomes. Read More ›

The prevalence of transthyretin cardiac amyloidosis was nearly 28% in patients diagnosed with heart failure with preserved ejection fraction who have ≥2 red flags for cardiac amyloidosis. Read More ›

Amyloidosis identified as the cause of heart failure in nearly 1 in 10 internal medicine patients. Read More ›

Evaluating potential response to therapy for cardiac transthyretin amyloidosis with single-photon emission computerized tomography/computed tomography quantification of 99mTc-PYP uptake. Read More ›

Page 3 of 4

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.